Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis.
Vandyke
K
K
Dewar
A L
AL
Farrugia
A N
AN
Fitter
S
S
Bik To
L
L
Hughes
T P
TP
Zannettino
A C W
AC
D000818:Animals; D001853:Bone Marrow / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D000069439:Dasatinib; D018841:HSP90 Heat-Shock Proteins / Q000378:metabolism; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive; D008264:Macrophages / Q000166:cytology / Q000187:drug effects; D051379:Mice; D022423:Myeloid Cells / Q000187:drug effects; D010010:Osteoclasts / Q000187:drug effects*; D010766:Phosphorylation / Q000187:drug effects; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*; D016186:Receptor, Macrophage Colony-Stimulating Factor / Q000378:metabolism; D013844:Thiazoles / Q000494:pharmacology*; D019061:src-Family Kinases / Q000378:metabolism
D018841:HSP90 Heat-Shock Proteins; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D016186:Receptor, Macrophage Colony-Stimulating Factor; D019061:src-Family Kinases; D000069439:Dasatinib